Fig. 4. Anti-Müllerian hormone receptor II (AMHR2)-extracellular domain (ED) vaccination formulated with AddaVax is highly effective in treating mouse epithelial ovarian carcinomas (EOCs). Therapeutic AMHR2-ED vaccination of ID8 inoculated C57BL/6 female mice using AddaVax as adjuvant resulted in (A) significant inhibition of ID8 tumor growth and (B) significant enhancement of overall survival. Error bars indicate ±standard deviation and asterisks indicate significance.
